219 related articles for article (PubMed ID: 33971920)
1. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.
McGovern MM; Wasserstein MP; Bembi B; Giugliani R; Mengel KE; Vanier MT; Zhang Q; Peterschmitt MJ
Orphanet J Rare Dis; 2021 May; 16(1):212. PubMed ID: 33971920
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy.
Jones SA; McGovern M; Lidove O; Giugliani R; Mistry PK; Dionisi-Vici C; Munoz-Rojas MV; Nalysnyk L; Schecter AD; Wasserstein M
Mol Genet Metab; 2020; 131(1-2):116-123. PubMed ID: 32616389
[TBL] [Abstract][Full Text] [Related]
3. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases.
Cassiman D; Packman S; Bembi B; Turkia HB; Al-Sayed M; Schiff M; Imrie J; Mabe P; Takahashi T; Mengel KE; Giugliani R; Cox GF
Mol Genet Metab; 2016 Jul; 118(3):206-213. PubMed ID: 27198631
[TBL] [Abstract][Full Text] [Related]
4. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.
Lipiński P; Kuchar L; Zakharova EY; Baydakova GV; Ługowska A; Tylki-Szymańska A
Orphanet J Rare Dis; 2019 Feb; 14(1):55. PubMed ID: 30795770
[TBL] [Abstract][Full Text] [Related]
5. [Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: A retrospective multicentric study of 28 adult cases].
Lidove O; Belmatoug N; Froissart R; Lavigne C; Durieu I; Mazodier K; Serratrice C; Douillard C; Goizet C; Cathebras P; Besson G; Amoura Z; Tazi A; Gatfossé M; Rivière S; Sené T; Vanier MT; Ziza JM
Rev Med Interne; 2017 May; 38(5):291-299. PubMed ID: 27884455
[TBL] [Abstract][Full Text] [Related]
6. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
Wasserstein MP; Lachmann R; Hollak C; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Hennermann JB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Thurberg BL; Yarramaneni A; Armstrong NM; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Dec; 18(1):378. PubMed ID: 38042851
[TBL] [Abstract][Full Text] [Related]
7. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients.
Hollak CE; de Sonnaville ES; Cassiman D; Linthorst GE; Groener JE; Morava E; Wevers RA; Mannens M; Aerts JM; Meersseman W; Akkerman E; Niezen-Koning KE; Mulder MF; Visser G; Wijburg FA; Lefeber D; Poorthuis BJ
Mol Genet Metab; 2012 Nov; 107(3):526-33. PubMed ID: 22818240
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
Diaz GA; Giugliani R; Guffon N; Jones SA; Mengel E; Scarpa M; Witters P; Yarramaneni A; Li J; Armstrong NM; Kim Y; Ortemann-Renon C; Kumar M
Orphanet J Rare Dis; 2022 Dec; 17(1):437. PubMed ID: 36517856
[TBL] [Abstract][Full Text] [Related]
9. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).
McGovern MM; Avetisyan R; Sanson BJ; Lidove O
Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103
[TBL] [Abstract][Full Text] [Related]
10. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective.
Pokrzywinski R; Hareendran A; Nalysnyk L; Cowie S; Crowe J; Hopkin J; Joshi D; Pulikottil-Jacob R
Sci Rep; 2021 Oct; 11(1):20972. PubMed ID: 34697402
[TBL] [Abstract][Full Text] [Related]
11. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus.
Scarpa M; Barbato A; Bisconti A; Burlina A; Concolino D; Deodato F; Di Rocco M; Dionisi-Vici C; Donati MA; Fecarotta S; Fiumara A; Galeone C; Giona F; Giuffrida G; Manna R; Mariani P; Pession A; Scopinaro A; Spada M; Spandonaro F; Trifirò G; Carubbi F; Cappellini MD
Intern Emerg Med; 2023 Apr; 18(3):831-842. PubMed ID: 36882619
[TBL] [Abstract][Full Text] [Related]
12. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
Lachmann RH; Diaz GA; Wasserstein MP; Armstrong NM; Yarramaneni A; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Apr; 18(1):94. PubMed ID: 37098529
[TBL] [Abstract][Full Text] [Related]
13. Combined Emphysema and Interstitial Lung Disease as a Rare Presentation of Pulmonary Involvement in a Patient with Chronic Visceral Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B).
Opoka L; Wyrostkiewicz D; Radwan-Rohrenschef P; Roży A; Tylki-Szymańska A; Tomkowski W; Szturmowicz M
Am J Case Rep; 2020 Aug; 21():e923394. PubMed ID: 32759889
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
[TBL] [Abstract][Full Text] [Related]
15. Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency.
Wang NL; Lin J; Chen L; Lu Y; Xie XB; Abuduxikuer K; Wang JS
BMC Gastroenterol; 2022 May; 22(1):227. PubMed ID: 35534800
[TBL] [Abstract][Full Text] [Related]
16. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).
Geberhiwot T; Wasserstein M; Wanninayake S; Bolton SC; Dardis A; Lehman A; Lidove O; Dawson C; Giugliani R; Imrie J; Hopkin J; Green J; de Vicente Corbeira D; Madathil S; Mengel E; Ezgü F; Pettazzoni M; Sjouke B; Hollak C; Vanier MT; McGovern M; Schuchman E
Orphanet J Rare Dis; 2023 Apr; 18(1):85. PubMed ID: 37069638
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis.
Cappellini MD; Motta I; Barbato A; Giuffrida G; Manna R; Carubbi F; Giona F
Eur J Intern Med; 2023 Feb; 108():81-84. PubMed ID: 36443133
[TBL] [Abstract][Full Text] [Related]
18. Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease.
Oliva P; Schwarz M; Mechtler TP; Sansen S; Keutzer J; Prusa AR; Streubel B; Kasper DC
Mol Genet Metab; 2023 May; 139(1):107563. PubMed ID: 37086570
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein non-metastatic protein B (GPNMB) plasma values in patients with chronic visceral acid sphingomyelinase deficiency.
Eskes ECB; van der Lienden MJC; Sjouke B; van Vliet L; Brands MMMG; Hollak CEM; Aerts JMFG
Mol Genet Metab; 2023 Aug; 139(4):107631. PubMed ID: 37453187
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Wasserstein M; Lachmann R; Hollak C; Arash-Kaps L; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Chen Y; Furey S; Thurberg BL; Zaher A; Kumar M
Genet Med; 2022 Jul; 24(7):1425-1436. PubMed ID: 35471153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
